We have qualitatively reviewed this strategy and reaffirmed its Process and People ratings. Fidelity’s Health Care Sector strategy is compelling for its superb portfolio manager, deep analytical resources, and thoughtful investment approach. The remainder of this analysis is from July 18, 2023.
Fidelity Advisor Health Care I FHCIX
- NAV / 1-Day Return 71.39 / +0.34 %
- Total Assets 4.6 Bil
-
Adj. Expense Ratio
0.720%
- Expense Ratio 0.720%
- Distribution Fee Level Below Average
- Share Class Type Institutional
- Category Health
- Investment Style Large Growth
- Min. Initial Investment —
- Status Open
- TTM Yield —
- Turnover 47%
USD | NAV as of Jul 26, 2024 | 1-Day Return as of Jul 26, 2024, 10:12 PM GMT+0
Morningstar’s Analysis FHCIX
Will FHCIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 52.0
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Boston Scientific Corp | 11.02 | 502.5 Mil | Healthcare |
Eli Lilly and Co | 8.50 | 387.6 Mil | Healthcare |
UnitedHealth Group Inc | 6.79 | 309.6 Mil | Healthcare |
Danaher Corp | 6.67 | 304.3 Mil | Healthcare |
Merck & Co Inc | 4.24 | 193.3 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 4.01 | 182.8 Mil | Healthcare |
Penumbra Inc | 3.32 | 151.6 Mil | Healthcare |
The Cigna Group | 3.30 | 150.3 Mil | Healthcare |
CVS Health Corp | 2.09 | 95.4 Mil | Healthcare |
Centene Corp | 2.01 | 91.6 Mil | Healthcare |